


Figure 1

**Fig. 1**


**Scheme 1. Modification of SBL mutants with Chiral Auxiliaries.**



The corresponding (S) MTS ligands follow the same code scheme (i.e. (S)-a, (S)-b, (S)-d, (S)-e, (S)-f, (S)-g, (S)-h, (S)-i).

**Fig. 2**


## Scheme 2. Synthesis of Mandelate-based Ligands



Reagents: (i)  $\text{Me}_2\text{SO}_4$ ,  $\text{NaOH}$ ,  $\text{H}_2\text{O}$ , 37%; (ii)  $\text{MeOH}$ ,  $\text{H}^+$ ; (ii)  $\text{MOM-Cl}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $\text{Et}_3\text{N}$  (90% 2 steps);  
 (iv) For  $(R)\text{-}3$ :  $\text{BH}_3$ ,  $\text{THF}$ , 82%; For  $(R)\text{-}5$ :  $\text{LiBH}_4$ ,  $\text{THF}$ , 97%; (v)  $\text{MeSO}_2\text{Cl}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $\text{Et}_3\text{N}$ ;  
 For  $(R)\text{-}8$ : 100%; (vi)  $\text{LiBr}$ , acetone; For  $(R)\text{-}10$ : 84%; For  $(R)\text{-}11$ : 78% 2 steps; (vii)  $\text{NaSSO}_2\text{CH}_3$ ,  $\text{DMF}$ ;  
 For  $(R)\text{-}12$ : 61%; (viii)  $\text{TFA}$ ,  $\text{H}_2\text{O}$ , 82%.

Fig. 3


## Scheme 3. Synthesis of Oxazolidinone-based Ligands



Reagents: (i) KOH, DMSO, Br (CH<sub>2</sub>)<sub>n</sub>Br,  
(ii) NaSSo<sub>2</sub>CH<sub>3</sub>, DMF.



**Fig. 4**


## Scheme 4. Synthesis of Indanol-based Ligands





Reagents: (i) triphosgene, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 100%;  
 (ii) KOH, DMSO, Br(CH<sub>2</sub>)<sub>3</sub>Br; (iii) NaSSO<sub>2</sub>CH<sub>3</sub>,  
 DMF.


Fig. 5

**Fig. 6A****Fig. 6B**

**Fig. 6C**

**Fig. 7A****Fig. 7B**



**Fig. 8**